Document Detail

"Tenecteplase--the best among the equals.".
MedLine Citation:
PMID:  20635761     Owner:  NLM     Status:  MEDLINE    
Tenecteplase is a genetically engineered product of the Alteplase molecule. Mutations of Alteplase at three locations result in a more fibrin specific thrombolytic agent with a longer half life. Such properties would allow bolus administration, leading to faster reperfusion of occluded arteries. Tenecteplase is equivalent to front loaded Alteplase in terms of mortality and is the only bolus thrombolytic drug for which equivalence has been demonstrated. Tenecteplase seems more potent than Alteplase when symptoms duration is more than 4 hours. Moreover, Tenecteplase significantly reduces the rate of major bleeds and the need for blood transfusion. The efficacy of Tenecteplase may be further improved by reducing re-infarction rate by enoxaparin instead of unfractionated heparin. Several large scale Clinical trials of Tenecteplase in acute myocardial infarction (MI) has been done making this drug truly evidence based. Available randomized studies and international clinical registries reveal that pre hospital thrombolysis by Tenecteplase is as effective as primary angioplasty. In fact Tenecteplase is now included in many prehospital thrombolytic reperfusion protocols, such as the Vienna STEMI registry, The Mayoclinic STEMI protocol and the French FAST-MI registry. Tenecteplase with so many evidence based advantages is a fair option in acute MI patients in whom primary PCI can not be offered due to logistic reasons.
R K Saran; R Sethi; M Nagori
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Indian heart journal     Volume:  61     ISSN:  0019-4832     ISO Abbreviation:  Indian Heart J     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374675     Medline TA:  Indian Heart J     Country:  India    
Other Details:
Languages:  eng     Pagination:  454-8     Citation Subset:  IM    
Department of Cardiology, CSM Medical University, Lucknow, Uttar Pradesh, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Combined Modality Therapy
Emergency Medical Services
Fibrinolytic Agents / therapeutic use*
Heparin / therapeutic use
Myocardial Infarction / drug therapy*,  therapy
Randomized Controlled Trials as Topic
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/tenecteplase; 9005-49-6/Heparin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pre-hospital thrombolysis.
Next Document:  Role of tenecteplase in pulmonary embolism.